ArticleScientific reports2026
Combined carcinoembryonic antigen, carbohydrate antigen 50, and neutrophil gelatinase-associated lipocalin distinguish benign and malignant pleural effusions: a Bayesian analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The value of pleural fluid neutrophil gelatinase-associated lipocalin (NGAL) in distinguishing malignant (MPE) and benign pleural effusions (BPE) remains unclear. This study aimed to evaluate the diagnostic accuracy of pleural fluid NGAL in differentiating MPE from BPE. We prospectively enrolled patients presenting with undiagnosed pleural effusion at the Affiliated Hospital of Inner Mongolia Medical University between September 2018 and July 2021. Their pleural fluid NGAL levels were measured using a Luminex platform. Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic performance of NGAL, carcinoembryonic antigen (CEA), and carbohydrate antigen 50 (CA50) for MPE. Bayesian likelihood ratio analysis was employed to calculate each biomarker's likelihood ratios (LRs). A total of 153 participants were included, comprising 66 cases with MPE and 87 cases with BPE. Pleural fluid NGAL levels were significantly higher in MPE than in BPE. The area under the ROC curve (AUC) of NGAL for diagnosing MPE was 0.72 (95% CI: 0.63-0.80). When combined with CEA and CA50, the AUC increased to 0.88 (95% CI: 0.82-0.94), with a sensitivity of 0.82 (0.70-0.90) and specificity of 0.87 (0.79-0.94). The posterior probability of MPE based on the combined use of the three biomarkers was 0.967. Pleural fluid NGAL demonstrates moderate diagnostic performance for MPE and can serve as an auxiliary biomarker in clinical practice. The combination of NGAL, CEA, and CA50 represents a useful diagnostic tool for MPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.